[go: up one dir, main page]

WO2008017278A2 - Crystalline tolterodine tartarate and a pharmaceutical composition containing the same - Google Patents

Crystalline tolterodine tartarate and a pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2008017278A2
WO2008017278A2 PCT/CZ2007/000078 CZ2007000078W WO2008017278A2 WO 2008017278 A2 WO2008017278 A2 WO 2008017278A2 CZ 2007000078 W CZ2007000078 W CZ 2007000078W WO 2008017278 A2 WO2008017278 A2 WO 2008017278A2
Authority
WO
WIPO (PCT)
Prior art keywords
tolterodine
pharmaceutical composition
tartarate
active substance
crystallization
Prior art date
Application number
PCT/CZ2007/000078
Other languages
French (fr)
Other versions
WO2008017278A3 (en
WO2008017278B1 (en
Inventor
Martin Svoboda
Josef Jampilek
Martina Kacirkova
Vaclav Tomasek
Mikulas Lehocky
Ludmila Hejtmankova
Vaclav Vosatka
Original Assignee
Zentiva, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CZ20060506A external-priority patent/CZ298448B6/en
Priority claimed from CZ20070160A external-priority patent/CZ302585B6/en
Application filed by Zentiva, A.S. filed Critical Zentiva, A.S.
Priority to EA200900294A priority Critical patent/EA016325B1/en
Priority to EP07785505A priority patent/EP2054372A2/en
Priority to US12/376,947 priority patent/US20100189786A1/en
Publication of WO2008017278A2 publication Critical patent/WO2008017278A2/en
Publication of WO2008017278A3 publication Critical patent/WO2008017278A3/en
Publication of WO2008017278B1 publication Critical patent/WO2008017278B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives

Definitions

  • the invention concerns the salt of 2-[(lR)-3-[bis(l-methylethyl)amino]-l-phenyl ⁇ ro ⁇ yl]-4- methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, a known urine spasmolytic, in an advantageous crystalline form for preparation of a pharmaceutical composition.
  • the invention also concerns a pharmaceutical composition containing tolterodine with exceptionally good stability.
  • Tolterodine is a known antagonist of cholinergic receptors, which is used for treatment of unstable urinary bladder, which in turn is associated with urine incontinency.
  • Tolterodine is usually used in the form of salts.
  • the most frequently used is the salt with (2R,3R)-2,3-dihydroxybutanedioic acid (1:1), known also under the name L-tartaric acid.
  • Tolterodine a method of its synthesis and its pharmacological effects were first described in patent EP 325 571.
  • the final step of the preparation of R-tolterodine tartarate is described in Example 9 of the mentioned document.
  • Racemic tolterodine is dissolved in ethanol.
  • An alcoholic solution of tartaric acid is added to the solution.
  • the mixture is heated for several minutes and then cooled down, which causes crystallization.
  • the product is again recrystallized from ethanol.
  • composition described in EP 325 571 has the following composition:
  • the composition was compressed to tablets, which could but did not have to be further coated.
  • the composition registered and sold in the Czech Republic corresponds, at least qualitatively, to the above mentioned description, and the version with coating has been selected.
  • the coating is constituted by hydroxypropylmethylcellulose, microcrystalline cellulose, stearic acid and titanium dioxide (data are known only qualitatively).
  • the registered product is wrapped in blisters made of polyvinylchloride, which is coated with a layer of polyvinylidenechloride (PVC/PVDC).
  • composition containing the product prepared in this way achieves the required release rate of the active substance, which is in turn directly associated with the pharmacological effectiveness of the product.
  • a usual strategy is decreasing the size of crystals. The above described crystallization yields large crystals, which do not allow sufficiently fast release of the active substance and are unsuitable for use.
  • the present invention solves the mentioned problems.
  • the subject matter of the invention consists in a crystalline salt of 2-[(lR)-3-[bis(l- methylethyl)amino]-l-phenylpropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, having the following parameters: a) at least 90 % of all the crystals are present in a size smaller than 30 ⁇ m, b) at least 40 % of crystalline matter are smaller than 250 ⁇ m, c) maximum size of crystals does not exceed 800 ⁇ m, and the purity of which can be further characterized in the following way: d) it contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) gives a value lower than 0.1 %.
  • the present invention further consists in a pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts which, apart from the active substance, contains at least one auxiliary substance from the group of fillers, disintegrants or lubricants, none of said auxiliary substances containing ions of alkaline earth metals.
  • substances based on carbohydrates can be used as fillers, especially cellulose, starch, lactose or other mono-, oligo- or poly-saccharides.
  • the amount of the filler in the composition ranges from 70 to 95 %. It is advantageous to use microcrystalline cellulose as the filler.
  • disintegrant system For the disintegrant system, one can use for example crospovidone, croscarmellose, carboxymethylstarch.
  • the content of the disintegrant in a tablet ranges from 2 to 10 %.
  • Sodium carboxymethylstarch has turned out to be a preferable disintegrant.
  • Sodium stearyl fumarate, stearic acid, hydrogenated castor oil or aluminum stearate can be used as lubricants. According to the invention, the content of lubricant ranges from 0.5 to 4 %.
  • a composition with these parameters has surprisingly turned out to be significantly more stable than the above-mentioned composition known from the prior art. While in the commercially-sold package of the known composition the content of impurities increased from virtually zero to about 0.8 % after 6 months of storing at 40 °C and relative humidity of 75 %, in the composition according to the invention the content of impurities does not increase by more than 0.1 % (weight percents) under the given conditions. The highest content of individual impurity was almost 0.4 % in the case of the known composition; it did not increase by more than 0.05 % in the composition according to the invention.
  • a preferable embodiment of the present invention includes a pharmaceutical composition with said crystalline salt.
  • composition using the standard test of active-substance release according to Pharm. Eur. with the paddle method at 50 rpm in the 0. IM HCl medium, at least 40 weight % of the total content of the active substance is dissolved within 5 minutes and at least 60 % in a phosphate buffer pH 6.8 under the same conditions.
  • composition according to the invention can be prepared via various methods.
  • the methods differ especially with respect to processing of the mixture designed for compression. Because of problems with stability of the preparative, it is better to find a mixture that can be directly tabletted, i.e. compressed without any previous processing. Finding such a mixture leads to further improvement of stability.
  • the most advantageous solution according to the invention is the one that is produced via direct compression and preferably contains sodium carboxymethylstarch as the disintegrant and sodium stearyl fumarate as the lubricant.
  • the composition is compressed to tablets and furnished with a coating.
  • the present invention also includes a procedure how to obtain said newly discovered form of the substance.
  • the procedure involves the hitherto undescribed process of crystallization from water.
  • the procedure preferably comprises suspending crude R-tolterodine tartarate in water, heating the suspension to boil, and maintaining at this temperature until dissolution, followed by crystallization by cooling down of the solution. It is advantageous to use weight ration of R- tolterodine tartarate to water from 1 : 5 to 1 : 20, preferably from 1 : 7 up to 1 : 15.
  • the procedure can be performed in such a way that the racemic salt of tolterodine hydrogenbromide is converted, by means of a base, to tolterodine, which is subsequently converted to tartarate by reaction with tartaric acid in a solution of a Cl to C3 alcohol and the corresponding diastereoisomer is crystallized and, after optional crystallization of the product from ethanol, the final crystallization is performed from water.
  • R-tolterodine tartarate is poorly soluble in water and, therefore, problems with the rate of its release into water media could be anticipated.
  • the release rate plays an important role in bioavailability of the product.
  • a common strategy how to improve the availability is grinding of the product.
  • R-tolterodine tartarate it was very difficult to grind the particles. It has turned out that the particles contained either too large crystals or too high content of powder particles, which made it difficult to handle the material.
  • the pharmaceutical composition is a mixture of:
  • the composition according to the invention was prepared in the form of coated tablets. It has turned out that it displays excellent release profiles of active substance. Especially in the neutral environment of the phosphate buffer (pH 6.8), a substantial portion of the active substance was released already during the first 5 minutes.
  • the composition containing the active substance in an amount of from 1 to 2.5 %, from 70 to 95 % of a filler, from 2 to 10 % of a disintegrant and from 0.5 to 4 % of a lubricant has turned out to be advantageous, the lubricant being selected from the group of substances including sodium stearyl fumarate, stearic acid, hydrogenated castor oil and aluminum stearate, or their combinations.
  • R-tolterodine tartarate itself belongs to pharmaceutical ingredients that are poorly soluble in cold water, which results in the above-mentioned problems with release of the active- substance from the pharmaceutical composition into aqueous media. This is probably why crystallization from ethanol is described in the literature.
  • the drawings represent results of measurement of the particle size of the product prepared according to Example 2 by a microscopic method.
  • Figure 1 represents batch I, where 91.95 % of all particles are smaller than 30 ⁇ m; 40.9 % of weight of the material would pass through the 250 ⁇ m sieve and the maximum crystal size is 623 ⁇ m.
  • Figure 2 represents batch II, where 94.73 % of particles are smaller than 30 ⁇ m; 47.2 % of weight of the material would pass through the 250 ⁇ m sieve and the maximum crystal size is 439 ⁇ m.
  • Figure 3 represents batch III, where 89.29 % of particles are smaller than 30 ⁇ m; 41.3 % of weight of the material would pass through the 250 ⁇ m sieve and the maximum crystal size is 702 ⁇ m.
  • Example 1 The pharmaceutical composition according to EP 325 571
  • composition core - coating
  • the left column presents the content of the highest-amount impurity and the right column presents the sum of all impurities.
  • the product is unsatisfactory with respect to the content of impurities after 3 months at 40 °C/ 75 % r.h., after 6 months at 30 °C/ 65 % r.h. and after 9 months at the normal conditions, i.e. 25 0 C/ 60 % r.h. See the tables of stability evaluation. Stability evaluation
  • a new composition without calcium hydrogenphosphate dihydrate and magnesium stearate was replaced by sodium stearyl fumarate.
  • the mixture was prepared in a homogenizer of the rotating-pinion type. A mixture of the first four components was stirred for 15 minutes after sifting, followed by addition of sodium stearyl fumarate, and the mixture was homogenized for additional 5 minutes. Then, the mixture was transported, using a belt conveyor, to a tablet forming machine, where it was compressed. Example 6. Testing of crystallization
  • R-tolterodine tartarate was prepared according to the scheme:
  • Tolterodine hydrogenbromide 7 was stirred in a mixture of 5% Na 2 CO 3 and dichloromethane until the product dissolved, about 1 hour. The organic phase was separated and filtered. The aqueous phase was extracted twice more with dichloromethane. The combined organic phases were extracted with water and concentrated in a rotary vacuum evaporator. The obtained tolterodine base was dissolved in ethanol and a solution of L(+)tartaric acid in ethanol was added. After adding a seed, the solution was left without stirring at room temperature until the next day.
  • the crude product was crystallized from ethanol, Batch I three times, Batches II and III twice, about 50 liters of the solvent for 1 kg of R(+)tolterodine tartarate.
  • the fourth crystallization of Batch I and the third crystallization of Batches II and Batch III were performed from water, about 10 liters of water for 1 kg of R(+)tolterodine tartarate.
  • Batch I 1.0 kg, i.e. 47.4 % HPLC quality 99.63 % S(-)tolterodine
  • Batch II 2.4 kg, i.e. 57.0 % 99.70 %
  • Batch III 2.1 kg, i.e. 47.2 % 99.84 % 13.4 %
  • Batch I 0.87 kg, i.e. 80.0 % HPLC quality 99.77 % SQtolterodine 3.3 %
  • Batch II 1.74 kg, i.e. 72.5 % 99.70 % 3.7 %
  • Batch III 1.60 kg, i.e. 76.2 % 99.27 % 3.2 %
  • Batch III 1.13 kg, i.e. 85.0 % 100.0 % ⁇ 0.07 %
  • Batch III (Fig. 3): 89.29 % of particles smaller than 30 ⁇ m; 41.3 % of weight of the material would pass through the 250 ⁇ m sieve and the maximal crystal size is 702 ⁇ m.
  • R-tolterodine tartarate prepared in Example 3 was used for manufacturing a pharmaceutical composition by direct compression (tabletting without previous processing of the tablet- forming mixture).
  • composition for 1 and 2 mg strengths of R-tolterodine tartarate Composition for 1 and 2 mg strengths of R-tolterodine tartarate.
  • More than 70 % of the active substance is dissolved in 5 minutes and more than 90 % in 20 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A crystalline salt of 2-[(1R)-3-[bis(l-methylethyl)amino]-1-ρhenylρropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90 % of all crystals are present in a size smaller than 30 μm, b) at least 40 % of crystalline matter are smaller than 250 μm, c) the maximum size of crystals does not exceed 800 μm, d) the salt contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1%. The method of its preparation involves at least one crystallization from water. A pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.

Description

Crystalline tolterodine tartarate and a pharmaceutical composition containing the same
Technical Field
The invention concerns the salt of 2-[(lR)-3-[bis(l-methylethyl)amino]-l-phenylρroρyl]-4- methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, a known urine spasmolytic, in an advantageous crystalline form for preparation of a pharmaceutical composition. The invention also concerns a pharmaceutical composition containing tolterodine with exceptionally good stability.
Background Art
Tolterodine is a known antagonist of cholinergic receptors, which is used for treatment of unstable urinary bladder, which in turn is associated with urine incontinency.
2-[(lR)-3-[bis(l-methylethyl)amino]-l-phenylpropyl]-4-methyl-phenol, known under the name tolterodine, alternatively R-tolterodine, is used in a drug composition in the form of its salt with (2R,3R)-2,3-dihydroxybutanedioic acid of formula I
Figure imgf000002_0001
Tolterodine is usually used in the form of salts. The most frequently used is the salt with (2R,3R)-2,3-dihydroxybutanedioic acid (1:1), known also under the name L-tartaric acid.
Tolterodine, a method of its synthesis and its pharmacological effects were first described in patent EP 325 571. The final step of the preparation of R-tolterodine tartarate is described in Example 9 of the mentioned document. Racemic tolterodine is dissolved in ethanol. An alcoholic solution of tartaric acid is added to the solution. The mixture is heated for several minutes and then cooled down, which causes crystallization. In order to obtain the pure substance, the product is again recrystallized from ethanol.
Purity of thus obtained R-tolterodine tartarate is usually not quite satisfactory and the crystallization has to be repeated several times. As the examples below show, even after three recrystallizations, the content of undesirable S-tolterodine is still 0.2 %. hi spite of the fact that the content of organic impurities was satisfactory, the problem seemed to be with inorganic impurities, as follows from the result determination of sulfate ash in the amount 0.34 %. These results were borderline satisfactory and did not correspond to ever stricter requirements for pharmaceutically active ingredients. With repeated crystallizations, concentrations of impurities decrease only very slowly at the expense of increasing losses. The question, therefore, was whether the obtained purities are satisfactory for the pharmaceutical compositions or not.
The problem was stability of the pharmaceutical composition. Application of the commonly manufactured pharmaceutical composition mentioned in the cited EP 325 571 did not provide a sufficiently stable product; in the course of time, degradation products were found in the composition in higher concentrations than those tolerable.
The composition described in EP 325 571 has the following composition:
Figure imgf000003_0001
According to the cited patent document, the composition was compressed to tablets, which could but did not have to be further coated. The composition registered and sold in the Czech Republic corresponds, at least qualitatively, to the above mentioned description, and the version with coating has been selected. The coating is constituted by hydroxypropylmethylcellulose, microcrystalline cellulose, stearic acid and titanium dioxide (data are known only qualitatively). The registered product is wrapped in blisters made of polyvinylchloride, which is coated with a layer of polyvinylidenechloride (PVC/PVDC).
Stability tests showed (Example 1) that while the composition is borderline satisfactory with respect to the stability requirement, the total increase of content of impurities is very high and in the case of improper storing, purity could decrease so much that the product would become unusable.
The problem, therefore, was to prepare a composition that would be absolutely acceptable with respect to stability.
Another problem is with ensuring that the composition containing the product prepared in this way achieves the required release rate of the active substance, which is in turn directly associated with the pharmacological effectiveness of the product. A usual strategy is decreasing the size of crystals. The above described crystallization yields large crystals, which do not allow sufficiently fast release of the active substance and are unsuitable for use.
Grinding of thus obtained crystals is difficult. The ground particles are significantly adhesive and tend to stick to the machinery or to form aggregates.
The present invention solves the mentioned problems.
Disclosure of Invention
The subject matter of the invention consists in a crystalline salt of 2-[(lR)-3-[bis(l- methylethyl)amino]-l-phenylpropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, having the following parameters: a) at least 90 % of all the crystals are present in a size smaller than 30 μm, b) at least 40 % of crystalline matter are smaller than 250 μm, c) maximum size of crystals does not exceed 800 μm, and the purity of which can be further characterized in the following way: d) it contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) gives a value lower than 0.1 %.
The present invention further consists in a pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts which, apart from the active substance, contains at least one auxiliary substance from the group of fillers, disintegrants or lubricants, none of said auxiliary substances containing ions of alkaline earth metals.
In the following detailed specification, all the mentioned percents are weight percents.
According to the invention, substances based on carbohydrates can be used as fillers, especially cellulose, starch, lactose or other mono-, oligo- or poly-saccharides. According to the invention, the amount of the filler in the composition ranges from 70 to 95 %. It is advantageous to use microcrystalline cellulose as the filler.
For the disintegrant system, one can use for example crospovidone, croscarmellose, carboxymethylstarch. The content of the disintegrant in a tablet ranges from 2 to 10 %. Sodium carboxymethylstarch has turned out to be a preferable disintegrant.
Sodium stearyl fumarate, stearic acid, hydrogenated castor oil or aluminum stearate can be used as lubricants. According to the invention, the content of lubricant ranges from 0.5 to 4 %.
A composition with these parameters has surprisingly turned out to be significantly more stable than the above-mentioned composition known from the prior art. While in the commercially-sold package of the known composition the content of impurities increased from virtually zero to about 0.8 % after 6 months of storing at 40 °C and relative humidity of 75 %, in the composition according to the invention the content of impurities does not increase by more than 0.1 % (weight percents) under the given conditions. The highest content of individual impurity was almost 0.4 % in the case of the known composition; it did not increase by more than 0.05 % in the composition according to the invention. A preferable embodiment of the present invention includes a pharmaceutical composition with said crystalline salt.
As turned out, said composition, using the standard test of active-substance release according to Pharm. Eur. with the paddle method at 50 rpm in the 0. IM HCl medium, at least 40 weight % of the total content of the active substance is dissolved within 5 minutes and at least 60 % in a phosphate buffer pH 6.8 under the same conditions.
The composition according to the invention can be prepared via various methods. The methods differ especially with respect to processing of the mixture designed for compression. Because of problems with stability of the preparative, it is better to find a mixture that can be directly tabletted, i.e. compressed without any previous processing. Finding such a mixture leads to further improvement of stability.
Accordingly, the most advantageous solution according to the invention is the one that is produced via direct compression and preferably contains sodium carboxymethylstarch as the disintegrant and sodium stearyl fumarate as the lubricant. Most preferably, the composition is compressed to tablets and furnished with a coating.
The present invention also includes a procedure how to obtain said newly discovered form of the substance. The procedure involves the hitherto undescribed process of crystallization from water.
The procedure preferably comprises suspending crude R-tolterodine tartarate in water, heating the suspension to boil, and maintaining at this temperature until dissolution, followed by crystallization by cooling down of the solution. It is advantageous to use weight ration of R- tolterodine tartarate to water from 1 : 5 to 1 : 20, preferably from 1 : 7 up to 1 : 15.
The procedure can be performed in such a way that the racemic salt of tolterodine hydrogenbromide is converted, by means of a base, to tolterodine, which is subsequently converted to tartarate by reaction with tartaric acid in a solution of a Cl to C3 alcohol and the corresponding diastereoisomer is crystallized and, after optional crystallization of the product from ethanol, the final crystallization is performed from water. Detailed description of the invention
The individual parameters of the substance R-tolterodine tartarate such as described, according to the problems which they solve:
Problem of stability of the pharmaceutical composition
The known pharmaceutical composition with the active ingredient produced by the know procedure, both according to patent document EP 325 571, did not provide a satisfactory substance. The composition was not stable and the active substance was not released in a sufficient rate.
Detailed testing of the product stability revealed that problems arise due to magnesium or calcium ions, which cause decomposition. For that reason, it was necessary to avoid these ions in the adjuvants. These ions are present in commonly used lubricants. Therefore, those lubricants were used for the composition that are selected from the group of substances including sodium stearyl fumarate, stearic acid, hydrogenated castor oil and aluminum stearate, or their combinations. This has ensured satisfactory short-term stabilities.
Considerations concerning a long-term stable formulation involved the apparent requirement to remove even trace amounts of these elements, which were determined in the first approximation via measuring the sulfate ashes. As far as stability is concerned, this impurity, therefore, has turned out to be very important. Considering the negative influence of these elements, it was clear that a substance that should be stable for a long time has to show low content of sulfate ash. Values below 0.3 % have turned out to be satisfactory.
Problem of the release rate
R-tolterodine tartarate is poorly soluble in water and, therefore, problems with the rate of its release into water media could be anticipated. The release rate plays an important role in bioavailability of the product. A common strategy how to improve the availability is grinding of the product. However, in the case of R-tolterodine tartarate, it was very difficult to grind the particles. It has turned out that the particles contained either too large crystals or too high content of powder particles, which made it difficult to handle the material.
Basically, it was possible to grind the material to very small particles and thus to obtain for example up to 90 % of all particles smaller than 30 μm. However, very small particles created aggregates, which probably did not disintegrate in the water medium, and the release rate problem thus was not solved completely. For a successful formulation, the condition of weight ratios has turned to be important; i.e. it is necessary that at least 40 % of all particles pass through the 250 μm sieve. The last condition included ruling out the incidence of isolated large crystals, hi spite the fact that their number is quite negligible, they can represent a significant share by weight. Therefore, no crystal should exceed 800 μm in size.
Problem of undesirable S-Tolterodine
Optical purity is an obvious important requirement for pharmaceutical substances. In the case of R-tolterodine tartarate, the content of the opposite enantiomer after three crystallizations from ethanol is about 0.2 %. This value has seemed to be satisfactory so far. However, the requirements concerning purity of the products usable in pharmaceutical compositions are getting ever stricter. Substances with the S-tolterodine content lower than 0.1 % are better suited to meet these new requirements.
The pharmaceutical composition
hi the preparation of the pharmaceutical composition the question was how the active pharmaceutical ingredient of new parameters would influence the properties of the pharmaceutical composition. The composition according to the invention was prepared in the form of coated tablets. It has turned out that it displays excellent release profiles of active substance. Especially in the neutral environment of the phosphate buffer (pH 6.8), a substantial portion of the active substance was released already during the first 5 minutes.
For combining the good release rate of the active substance with the stability of the pharmaceutical composition, the composition containing the active substance in an amount of from 1 to 2.5 %, from 70 to 95 % of a filler, from 2 to 10 % of a disintegrant and from 0.5 to 4 % of a lubricant has turned out to be advantageous, the lubricant being selected from the group of substances including sodium stearyl fumarate, stearic acid, hydrogenated castor oil and aluminum stearate, or their combinations.
Procedure for preparing the active ingredient
R-tolterodine tartarate itself belongs to pharmaceutical ingredients that are poorly soluble in cold water, which results in the above-mentioned problems with release of the active- substance from the pharmaceutical composition into aqueous media. This is probably why crystallization from ethanol is described in the literature.
Surprisingly, it has turned out that crystallization from water yields an active substance that meets the above-discussed parameters of the product.
Brief Description of Drawings
The drawings represent results of measurement of the particle size of the product prepared according to Example 2 by a microscopic method.
Figure 1 represents batch I, where 91.95 % of all particles are smaller than 30 μm; 40.9 % of weight of the material would pass through the 250 μm sieve and the maximum crystal size is 623 μm.
Figure 2 represents batch II, where 94.73 % of particles are smaller than 30 μm; 47.2 % of weight of the material would pass through the 250 μm sieve and the maximum crystal size is 439 μm.
Figure 3 represents batch III, where 89.29 % of particles are smaller than 30 μm; 41.3 % of weight of the material would pass through the 250 μm sieve and the maximum crystal size is 702 μm. Examples
The invention is illustrated in more detail in the following examples.
Example 1. The pharmaceutical composition according to EP 325 571
The same qualitative composition of the formulation as for the commercially sold product was used for preparation of laboratory batches.
Technology of direct compression was used for processing the formulation.
Commercially sold product 1 and 2 mg
Formulation - Coated tablets
Composition — core - coating
- microcrystalline cellulose - hypromellose - CaHPO4 . 2H2O - microcrystalline cellulose
- explotab - stearic acid
- magnesium stearate - titanium oxide
- colloidal silicon oxide
Table No. 1. Stability evaluation of the prepared product (labeled batch 020104) and of the commercially manufactured product
Figure imgf000010_0001
02 01 04 0.07 0.12 0.05 0.05 0.08 0.08 .07 0.07
Figure imgf000011_0001
Stability evaluation was performed in two packagings, PVC and PVC/PVDC.
For each type of packaging, the left column presents the content of the highest-amount impurity and the right column presents the sum of all impurities.
After 3 months at 40 °C and 75 % relative humidity, the sum of impurities increased to 0.56 % in the PVC packaging and to 0.36 % in the PVC/PVDC packaging. After 6 months at 40 °C and 75 % relative humidity, the sum of impurities increased to 0.92 % in the PVC packaging and to 0.83 % in the PVC/PVDC packaging, similarly as in the original commercially sold product. See Table No. 1.
Example 2 (reference):
A new composition without calcium hydrogenphosphate dihydrate was proposed for the pilot batches.
Core coating
- microcrystalline cellulose - hypromellose
- explotab - stearic acid
- magnesium stearate - titanium dioxide
- colloidal silicon oxide - microcrystalline cellulose
The product is unsatisfactory with respect to the content of impurities after 3 months at 40 °C/ 75 % r.h., after 6 months at 30 °C/ 65 % r.h. and after 9 months at the normal conditions, i.e. 25 0C/ 60 % r.h. See the tables of stability evaluation. Stability evaluation
Batch Number: 0413 09 04 PVC5Al blister, 40 0CIl 5 % r.h.
Figure imgf000012_0001
Batch Number: 0413 09 04 PVC5Al blister, 30 °C/65 % r.h.
Figure imgf000012_0002
Batch Number: 0413 09 04 PVC3Al blister, 25 °C/60 % r.h.
Figure imgf000013_0001
K Batch Number: 0513 09 04 PVC5Al blister, 40 °C/75 % r.h.
Figure imgf000013_0002
Batch Number: 0513 09 04 PVQAl blister, 30 °C/65 % r.h.
Figure imgf000014_0001
Batch Number: 0513 09 04 PVC3Al blister, 25 °C/60 % r.h.
Figure imgf000014_0002
Example 3
Stress tests:
In the following tests, an increase of impurities was measured for binary mixtures of the active agent and lubricant in ratio 1: 1.5 (weight) in humid air at the temperature of 80 0C, for 6 hours.
Stress tests
Figure imgf000015_0001
It has turned out that the increase of impurities in the presence of magnesium stearate is several times higher than in the case of other tested lubricants.
Example 4
A new composition without calcium hydrogenphosphate dihydrate and magnesium stearate. Magnesium stearate was replaced by sodium stearyl fumarate.
After 6 months at 40 0C/ 75 % r.h. as well as at 25 °C/ 60 % r.h.5 there is no increase of the content of impurities. See the tables of stability evaluation. Composition for 1 and 2 mg strengths of Tolterodine tartarate.
Figure imgf000016_0001
Stability evaluation
TOLTERODINE 1 tbl.flm., Batch Number: 10 01 06, Pilot batch Packaging: PVC/PVDC, Al, Storing conditions: 40 °C/75 % R.H.
Figure imgf000016_0002
Figure imgf000017_0001
TOLTERODINE 1 tbl.flm., Batch Number: 11 01 06, Pilot batch Packaging: PVC/PVDC, Al, Storing conditions: 40 °C/75 % R.H.
Figure imgf000017_0002
TOLTERODINE 1 tbl.flm., Batch Number: 10 01 06, Pilot batch Packaging: PVC/PVDC, Al, Storing conditions: 25 °C/60 % R.H.
Figure imgf000017_0003
TOLTERODINE 1 tbLflm., Batch Number: 11 01 06, Pilot batch Packaging: PVC/PVDC, Al, Storing conditions: 25 °C/60 % R.H.
Figure imgf000018_0001
Example 5
Similarly as the composition in Example 4, the following composition also showed very good stability properties:
Figure imgf000018_0002
The mixture was prepared in a homogenizer of the rotating-pinion type. A mixture of the first four components was stirred for 15 minutes after sifting, followed by addition of sodium stearyl fumarate, and the mixture was homogenized for additional 5 minutes. Then, the mixture was transported, using a belt conveyor, to a tablet forming machine, where it was compressed. Example 6. Testing of crystallization
R-tolterodine tartarate was prepared according to the scheme:
Figure imgf000019_0001
Apparatus: glass separator 80 1 equipped with a stirrer
Procedure: Tolterodine hydrogenbromide 7 was stirred in a mixture of 5% Na2CO3 and dichloromethane until the product dissolved, about 1 hour. The organic phase was separated and filtered. The aqueous phase was extracted twice more with dichloromethane. The combined organic phases were extracted with water and concentrated in a rotary vacuum evaporator. The obtained tolterodine base was dissolved in ethanol and a solution of L(+)tartaric acid in ethanol was added. After adding a seed, the solution was left without stirring at room temperature until the next day. After filtration, the crude product was crystallized from ethanol, Batch I three times, Batches II and III twice, about 50 liters of the solvent for 1 kg of R(+)tolterodine tartarate. The fourth crystallization of Batch I and the third crystallization of Batches II and Batch III were performed from water, about 10 liters of water for 1 kg of R(+)tolterodine tartarate.
Theoretical yield: 12.11 II 4.21 III 4.45 kg
Actual yield:
Batch I: 1.0 kg, i.e. 47.4 % HPLC quality 99.63 % S(-)tolterodine Batch II: 2.4 kg, i.e. 57.0 % 99.70 % Batch III: 2.1 kg, i.e. 47.2 % 99.84 % 13.4 %
1st crystallization:
Yield:
Batch I: 0.87 kg, i.e. 80.0 % HPLC quality 99.77 % SQtolterodine 3.3 % Batch II: 1.74 kg, i.e. 72.5 % 99.70 % 3.7 % Batch III: 1.60 kg, i.e. 76.2 % 99.27 % 3.2 %
IInd crystallization:
Yield:
Batch I: 0.62 kg, i.e. 77.5 % HPLC quality 99.85 % S(-)tolterodine 0.70
%
Batch II: 1.50 kg, i.e. 86.2 % not analyzed
0.76%
Batch III: 1.33 kg, i.e. 83.1 % 99.89 % 0.85
%
After two crystallizations from ethanol, the content of S-Tolterodine was still unsatisfactory.
IIIrd crystallization:
Yield:
Batch I: 0.53 kg, i.e. 85.5 % HPLC quality 99.73 % S(-)tolterodine 0.19
%
Batch II: 1.26 kg, i.e. 84.0 % 99.95 % <0.07
%
Batch III: 1.13 kg, i.e. 85.0 % 100.0 % <0.07 %
After crystallization from water, the content of S-tolterodine decreased to an immeasurable value (< 0.07 %) for both batches. In the case of crystallization from ethanol, it oscillated on the borderline of acceptability 0.2 %. After three crystallizations from ethanol, the content of sulfate ash was still not satisfactory in Batch I, it was 0.34 %. Therefore, one more crystallization was performed.
Batch I: 0.40 kg, i.e. 76.0 % HPLC quality 99.81 % S(-)tolterodine <0.07 %
After the crystallization, the content of sulfate ash was 0.03 %. The content of S-tolterodine also dropped to the expected value. For all the batches, measurement of particle size was performed without any treatment using the microscopic method.
Results:
Batch I (Fig. 1): 91.95 % of all particles smaller than 30 μm; 40.9 % of weight of the material would pass through the 250 μm sieve and the maximal crystal size is 623 μm.
Batch II (Fig. 2): 94.73 % of particles smaller than 30 μm; 47.2 % of weight of the material would pass through the 250 μm sieve and the maximal crystal size is 439 μm.
Batch III (Fig. 3): 89.29 % of particles smaller than 30 μm; 41.3 % of weight of the material would pass through the 250 μm sieve and the maximal crystal size is 702 μm.
Example 7
The most advantageous method of preparation of API
Tolterodine hydrobromide 7 in the amount 3.4 kg (8.4 mol) of was stirred in a mixture of 5% Na2CO3, which was prepared by dissolving 0.9 kg of sodium carbonate in water and adjusting the volume to 18 liters of the solution and 27 liters of dichloromethane for ca. 60 minutes. The organic phase was separated, the aqueous layer was extracted two more times with 5 liters of dichloromethane. The solvent was distilled out from the combined organic phases. The obtained tolterodine base was dissolved in 30 liters of ethanol and a solution of 1.26 kg (8.4 mol) of L(+)tartaric acid in 65 1 of ethanol was added. The solution was stirred for about 2 hours and then placed in a refrigerator at the temperature of about 5-8 °C. The next day the precipitated product was filtered. The crystals were washed with cold ethanol and dried. The crude product was first crystallized from ethanol. R-Tolterodine tartarate in the amount of 2.2 kg was dissolved in 110 liters of ethanol under reflux. The solution was left to cool down spontaneously without stirring until the next day. The precipitated crystals were filtered and dried. The final crystallization was performed from water. The product crystallized from ethanol in the amount 1.76 kg was dissolved in 18 liters of water under reflux. The solution was left to cool down spontaneously without stirring until the next day. The precipitated crystals were filtered and dried. 1.5 kg of R-tolterodine tartarate of declared quality were obtained. Example 8
R-tolterodine tartarate prepared in Example 3 was used for manufacturing a pharmaceutical composition by direct compression (tabletting without previous processing of the tablet- forming mixture).
Composition for 1 and 2 mg strengths of R-tolterodine tartarate.
Figure imgf000022_0001
After 6 months at 40 °C/75 % relative humidity as well as at 25 °C/60 % relative humidity, the content of impurities does not increase. See the tables of stability evaluation.
Figure imgf000023_0001
Release rate of the active substance under conditions defined in Pharm. Eur., measured with the paddle method at 50 rpm:
Release of active substance in 0.1 M HCl
Figure imgf000023_0002
It turns out that more than 50 % of the active substance is released already in 5 minutes, 90 % is released in 15 minutes, and virtually all the active substance is released after 30 minutes. Release of active substance in phosphate buffer at pH 6.8
Figure imgf000024_0001
More than 70 % of the active substance is dissolved in 5 minutes and more than 90 % in 20 minutes.

Claims

1. A crystalline salt of 2-[(lR)-3-[bis(l-methylethyl)amino]-l-phenylpropyl]-4-methyl- phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, characterized in that: a) at least 90 % of all crystals are present in a size smaller than 30 μm, b) at least 40 % of crystalline matter are smaller than 250 μm, c) the maximum size of crystals does not exceed 800 μm, d) it contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1 %.
2. A method of preparation of R-tolterodine tartarate according to claim 1, characterized in that it involves at least one crystallization of this substance from water.
3. The method according to claim 2, characterized in that crude R-tolterodine tartarate is suspended in water, the suspension is heated to boil, and is kept at this temperature until dissolution, followed by crystallization by cooling down the solution.
4. The method according to claim 3, characterized in that the weight ratio of R- tolterodine tartarate to water is from 1 : 5 to 1 : 20.
5. The method according to claim 8, characterized in that the weight ratio of R- tolterodine tartarate to water is from 1 : 7 to 1 : 15.
6. The method according to claims 2 through 5, characterized in that the racemic salt of tolterodine hydrogenbromide is first converted, by action of a base, to tolterodine, which is subsequently converted into the tartarate by reaction with tartaric acid in a solution of a Cl to C3 alcohol and the respective diastereoisomer is crystallized and, after optional crystallization of the product from ethanol, the final crystallization is performed from water.
7. A pharmaceutical composition containing tolterodine tartarate as the active substance, characterized in that it further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.
8. The pharmaceutical composition according to claim 7, characterized in that it is free OfMg2+ and Ca2+ ions.
9. The pharmaceutical composition according to claim 7, characterized in that it contains, by weight, the active substance in the amount of 1 to 2.5 %, 70 to 95 % of the filler, 2 to 10 % of the disintegrant and 0.5 to 4 % of the lubricant.
10. The pharmaceutical composition according to claim 7, characterized in that the lubricant is selected from the group including sodium stearyl fumarate, stearic acid, hydrogenated castor oil and aluminum stearate, or their combinations.
11. The pharmaceutical composition according to any of claims 7-10, characterized in that it contains the crystalline salt according to claim 1 as the active substance.
12. The pharmaceutical composition according to any of claims 7-10, characterized in that it contains R-tolterodine tartarate obtained by the method of any of claims 2-6 as the active substance.
13. The pharmaceutical composition according to claims 11 or 12, characterized in that in the standard test of release of the active substance according to Pharm. Eur. using the paddle method at 50 rpm, at least 40 weight % of the total content of the active substance is dissolved in 0.1M HCl within 5 minutes and at least 60 % is dissolved in the phosphate buffer, pH 6.8, under the same conditions.
PCT/CZ2007/000078 2006-08-09 2007-08-09 Crystalline tolterodine tartarate and a pharmaceutical composition containing the same WO2008017278A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EA200900294A EA016325B1 (en) 2006-08-09 2007-08-09 Method of preparation crystalline (r) tolterodine tartarate
EP07785505A EP2054372A2 (en) 2006-08-09 2007-08-09 Crystalline tolterodine tartarate and a pharmaceutical composition containing the same
US12/376,947 US20100189786A1 (en) 2006-08-09 2007-08-09 Crystalline tolterodine tartarate and a pharmaceutical composition containing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CZ20060506A CZ298448B6 (en) 2006-08-09 2006-08-09 Tolterodine-containing pharmaceutical composition
CZPV2006-506 2006-08-09
CZ20070160A CZ302585B6 (en) 2007-02-26 2007-02-26 Crystalline salt of 2-[(1R)-3-bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutandioic acid
CZPV2007-160 2007-02-26

Publications (3)

Publication Number Publication Date
WO2008017278A2 true WO2008017278A2 (en) 2008-02-14
WO2008017278A3 WO2008017278A3 (en) 2008-07-10
WO2008017278B1 WO2008017278B1 (en) 2008-08-28

Family

ID=38951261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2007/000078 WO2008017278A2 (en) 2006-08-09 2007-08-09 Crystalline tolterodine tartarate and a pharmaceutical composition containing the same

Country Status (4)

Country Link
US (1) US20100189786A1 (en)
EP (1) EP2054372A2 (en)
EA (1) EA016325B1 (en)
WO (1) WO2008017278A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20082055A1 (en) * 2008-11-19 2009-02-18 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF (R) -TOLTERODINE BASE FREE
ITMI20110410A1 (en) * 2011-03-15 2012-09-16 Cambrex Profarmaco Milano Srl PROCEDURE FOR THE PREPARATION OF (R) -TOLTERODINE L-TARTRATE OF DEFINED CRYSTALLINE SHAPE

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (en) * 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20082055A1 (en) * 2008-11-19 2009-02-18 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF (R) -TOLTERODINE BASE FREE
ITMI20110410A1 (en) * 2011-03-15 2012-09-16 Cambrex Profarmaco Milano Srl PROCEDURE FOR THE PREPARATION OF (R) -TOLTERODINE L-TARTRATE OF DEFINED CRYSTALLINE SHAPE

Also Published As

Publication number Publication date
EA200900294A1 (en) 2009-08-28
EA016325B1 (en) 2012-04-30
US20100189786A1 (en) 2010-07-29
EP2054372A2 (en) 2009-05-06
WO2008017278A3 (en) 2008-07-10
WO2008017278B1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
US8143315B2 (en) Salts of the active substance rasagiline
KR102050117B1 (en) Ivabradine hydrochloride form iv
CA2598407A1 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them
US8992976B2 (en) Pharmaceutical composition containing donepezil hydrochloride, tablets produced therefrom and methods for producing the same
WO2011069608A1 (en) S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
JP7168447B2 (en) Crystal forms of bilastine and methods for their preparation
JP2012512145A (en) Crystalline salt form of flibanserin
WO2008017278A2 (en) Crystalline tolterodine tartarate and a pharmaceutical composition containing the same
US7186863B2 (en) Sertraline compositions
JP6839708B2 (en) 8-[(3R) -3-amino-1-piperidinyl] -7- (2-butyne-1-yl) -3,7-dihydro-3-methyl-1- [4-methyl-2-quinazolinyl) methyl ] -A pharmaceutical composition containing -1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof.
AU2003264968A1 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2004094414A1 (en) Water soluble salts of risperidone
RU2193560C2 (en) Novel salt
US6316672B1 (en) Form a of fluoxetine hydrochloride
JP2024546098A (en) Rabeximod Compound
TWI532734B (en) Crystallization of Alesartan Ester and its preparation method and pharmaceutical composition containing the same
US6258853B1 (en) Form a of fluoxetine hydrochloride
IL303688A (en) Amorphous solid dispersions
JP2009507850A (en) Pharmaceutical dosage forms and compositions comprising lecozotan
EP3459538B1 (en) Crystalline salts of a dextroamphetamine prodrug
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
IL167659A (en) Crystalline sibutramine methanesulfonate hemihydrate, pharmaceutical compositions containing the same and methods for the preparation thereof
US6310250B1 (en) Form A of fluoxetine hydrochloride
EP2513042A2 (en) Solid dapoxetine
CZ302585B6 (en) Crystalline salt of 2-[(1R)-3-bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutandioic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07785505

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007785505

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12376947

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200900294

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU